Cost burden of treatment resistance in patients with depression

American Journal of Managed Care

Volumn 16, Issue 5, 2010, Pages 370-377

  Gibson, Teresa B ^a   Jing, Yonghua ^b   Carls, Ginger Smith ^a   Kim, Edward ^b   Bagalman, J Erin ^c   Burton, Wayne N ^d   Tran, Quynh Van ^e   Pikalov, Andrei ^e   Goetzel, Ron Z ^c,f  

^a THOMSON REUTERS   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c THOMSON REUTERS   (United Kingdom)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^f EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; MOOD STABILIZER;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; ARTICLE; BILLING AND CLAIMS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DRUG COST; ELECTROCONVULSIVE THERAPY; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; SEX DIFFERENCE;

ADULT; ANTIDEPRESSIVE AGENTS; COST OF ILLNESS; DEPRESSION; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MASSACHUSETTS; MIDDLE AGED; OBSERVATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77952836523     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kessler RC, Berglund P, Demier O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105.
2. Greenberg PE, Corey-Lisle PK, Birnbaum HG, Marynchenko MB, Claxton AJ. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics. 2004;22(6):363-373.
3. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*'D Study Team. Evaluation of outcomes with Citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
4. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
5. National Institute of Mental Health. Odds of beating depression diminish as additional treatment strategies are needed. November 1, 2006. http://www.nimh.nih.gov/science-news/2006/odds-of-beating-depression-diminish- as-additional-treatment-strategies-are-needed.shtml. Accessed April 5, 2009.
6. Berlim MT, Turecki G. Definition, assessment, and staging of treatment resistant refractory major depression: a review of current concepts and methods. Can Rev Psychiatry. 2007;52(1):46-54.
7. Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ. Identification of a claims data "signature" and economic consequences for treatment-resistant depression. J Clin Psychiatry. 2002;63(8):717-726.
8. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63(11):963-971. (Pubitemid 35388053)
9. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65(3):341-347.
10. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23-29.
11. Souery D, Amsterdam J, de Montigny C, et al.Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1-2):83-91. (Pubitemid 29073687)
12. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649-659.
13. Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005;25(4):336-341. (Pubitemid 41060253)
14. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853.
15. Marcus RN, McQuade RD, Carson WH, et al.The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165.
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
17. Ashcraft ML, Fries BE, Nerenz DR, et al. A psychiatric patient classification system. An alternative to diagnosis-related groups. Med Care. 1989;27(5):543-557.
18. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. http://www.bls.gov/cpi/. Accessed May 2, 2010.
19. Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Version 3.0.0. 2003. http://ideas.repec.org/c/boc/bocode/s432001.html. Accessed April 29, 2010.
20. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health economics. J Health Econ. 1998;17(3):247-281.
21. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005;24(3):465-488. (Pubitemid 40461909)
22. Sharma V, Khan M, Smith A. A closer look at treatment resistant depression: is it due to a bipolar diathesis? J Affect Disord. 2005;84(2-3):251-257.
23. Woo Y, Chae J, Jun T, Kim K, Bahk W. The bipolar diathesis of treatment-resistant major depressive disorder. Int J Psychiatry Clin Pract. 2008;12(12):142-146. ■ (Pubitemid 351883293)